Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2030?
Alright, let's talk about something that's really caught my eye on Kalshi, and honestly, it’s got me a little baffled. I've been watching the market, "Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2030?" and right now, the 'Yes' side is holding steady at 54%. That means traders are collectively giving it a 54% chance of getting the green light from the FDA sometime in the next five and a half years. The 'No' is sitting at 47%, which is what you’d expect when the market isn't at 50/50. It’s seen a modest 123 contracts traded, with 97 contracts of open interest, so it’s not exactly a blockbuster, but it’s enough activity to suggest people are paying attention.
Here's the thing you need to know, and it's why that 54% 'Yes' price looks incredibly optimistic to me right now: we just had a pretty significant event. On June 4th, the FDA's Psychopharmacologic Drugs Advisory Committee met to discuss Lykos Therapeutics' (the company behind MDMA-assisted therapy) application. Their vote? A resounding 10-1 against recommending approval. Ten to one! That's not a close call; that's a near-unanimous rejection from the very experts tasked with advising the FDA on these matters. My immediate reaction was: how is the 'Yes' still above 50% after that?
Now, I know what you might be thinking: an advisory committee recommendation isn't binding. And you're absolutely right, the FDA doesn't have to follow their advice. But in practice, they almost always do. To see the FDA go against such a lopsided advisory committee vote would be, frankly, extraordinary. It would be a monumental defiance of its own expert panel. I'm not saying it's impossible, but it would require a level of internal disagreement or external pressure that is rarely seen.
Let’s add another layer to this. This isn't just about an abstract approval by 2030. The PDUFA date – the deadline for the FDA to make its decision on Lykos's application – is set for August 11, 2024. That’s just a couple of months away. So, the question isn't really "before 2030" as much as it is "in the next few weeks, or a much, much longer time from now." If the FDA declines to approve it by August 11th, which seems highly probable given the advisory committee's recommendation, then the path to approval before 2030 becomes incredibly complicated. It would likely mean Lykos would need to conduct entirely new trials, address the committee's concerns about efficacy, safety, and trial integrity, and then resubmit. That entire process would push any potential approval well into the future, possibly past 2030, or significantly reduce the probability of it ever happening.
So, when I look at that 54% 'Yes' price, I can't help but feel like the market is either severely underestimating the weight of an advisory committee's 'No,' or it's betting on an unprecedented FDA decision to overturn its experts. My personal take? I'd be selling 'Yes' contracts all day long if I were in this market. I think the probability of approval by August 11th is extremely low now, and if it doesn't happen then, the chances of it happening by 2030 plummet dramatically. I don't see a clear, fast track to approval after such a definitive rejection from the committee. The market seems to be clinging to an older narrative, and I'm genuinely surprised it hasn't adjusted more sharply. It's a classic case where headline news (the vote) should, in my opinion, instantly reprice the odds, and yet, here we are, still hovering above an even money bet. Sometimes, even with all the information out there, these markets can be slow to react, or perhaps, just maybe, I'm missing something huge that gives the FDA a compelling reason to override its panel. But right now, I just don't see it.
